Don't miss a single story. Get it delivered to your inbox with our daily recap on what's moving the markets.

Khiron Life Sciences (KHRN.V) wisely spent 2018 laying the groundwork for its continued expansion throughout the Americas. As Abraham Lincoln once said, “Give me six hours to chop down a tree and I will spend the first four sharpening the ax.”

With two separate deals granting access to the U.S. and Brazilian markets, Khiron is well positioned to supply the burgeoning demand for cannabis on this side of the Atlantic and beyond.

Equity.Guru’s Ethan Reyes spoke with Khiron president, Chris Naprawa, to discuss the company’s progress in 2018, the tantalizing Brazilian market and what the sector can expect from Khiron in 2019.

Full disclosure: Khiron Life Sciences is an Equity.Guru marketing client.

Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Ethan Reyes

Ethan Reyes is a journalist, poet and screenwriter from Vancouver, B.C. His bylines have appeared in such publications as Macleans, the North Delta Reporter and XTRA!

Leave a Reply

2 Comments on "Equity.Guru podcast: Khiron Life Sciences (KHRN.V) discusses its 2018 performance and the Brazilian market"

Notify of
Sort by:   newest | oldest | most voted

One of the nominees for board of directors position is Sidney Himmel.
Check the AGM document for Khiron.
He was President & CEO of IC Potash (BGLV.CN) 2007-2015.
Terrible to be connected with Sidney Himmel.